Keith Lookingland, Ph.D.


Ph.D., University of Maryland

Development of Neuroprotective Pharmacological Agents and Strategies for the Treatment of Dopamine Neurodegenerative Disorders including Parkinson's Disease and Restless Legs Syndrome

Publications
Drolet, R.E., B. Behrouz, K.J. Lookingland and J.L. Goudreau, 2004. Mice lacking á-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25(5): 761-769.

Lookingland, K.J. and K.E. Moore, 2005. Functional neuroanatomy of hypothalamic dopaminergic neuroendocrine systems. In "Handbook of Chemical Neuroanatomy," Vol. 20, Chapter 8: 433-521.

Ni, W., C.S. Wilhelm, M. Bader, D.L. Murphy, K.J. Lookingland and S.W. Watts, 2005. (+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-HT or 5-HTT. J. Pharmacol. Exp. Ther. 314(3): 953-960.

McCall, R.B., K.J. Lookingland, P.J. Bedard and R.M. Huff, 2005. Sumanirole, a highly dopamine D2-selective receptor agonist: In vitro and in vivo pharmacologic characterization and efficacy in animal models of Parkinson´s disease. J. Pharmacol. Exp. Ther. 314(3): 1248-1256.

Drolet, R.E., B. Behrouz, K.J. Lookingland and J.L. Goudreau, 2006. Substrate-mediated enhancement of phosphorylated tyrosine hydroxyase in nigrostriatal dopamine neurons: Evidence for a role of á-synuclein. J. Neurochem. 96: 950-959.

Ni, W., K.J. Lookingland and S.W. Watts, 2006. Arterial 5-HT transporter function is impaired in DOCA and LNNA but not spontaneously hypertensive rats. Hypertension 48: 134-140.

Behrouz, B., R.E. Drolet, Z.A. Sayed, K.J. Lookingland, J.L. Goudreau, 2007, Unique responses to mitchondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult. Neuroscience 147: 592-598.